EyePoint's Eye Drug Worked — Except When It Didn't
EyePoint's DURAVYU promised to cut eye injections from monthly to twice a year. Its first pivotal trial delivered stunning durability data but missed the primary endpoint, leaving investors with a Rorschach test instead of a clear answer.
The Needle in the Eye Problem
Imagine getting a needle jabbed into your eyeball every month. Now imagine doing it for years.
That's the reality for millions of people with wet age-related macular degeneration (wet AMD), a condition where abnormal blood vessels leak fluid into the retina and slowly steal your vision. The standard treatment: anti-VEGF injections that block the proteins fueling those leaky vessels. Drugs like aflibercept and ranibizumab work well, but they need to be given every four to six weeks. Miss appointments, and your vision pays the price.
So when EyePoint Pharmaceuticals promised a therapy that could last six months or longer with a single shot, the ophthalmology world perked up. Their drug, DURAVYU, just reported topline results from LUGANO, the first of two pivotal Phase 3 trials.
The headline? It's complicated.
A Win Wrapped Inside a Loss
Let's start with what went wrong. DURAVYU did not meet its primary endpoint in the full patient population. That's the main thing the trial was designed to prove: that DURAVYU's vision outcomes were non-inferior (basically "at least as good as") to aflibercept given on its normal schedule.
In clinical trials, missing your primary endpoint is like losing the championship game. It doesn't matter how great your regular season was.
But EyePoint isn't waving the white flag. The company says a small, asymmetric subgroup (about 4% of patients) confounded the results. When they excluded that group in a secondary analysis, DURAVYU did show non-inferiority to aflibercept, with a nominal p-value of 0.0096. For the non-statisticians: that's a strong signal suggesting the result wasn't due to random chance.
The problem is that this was an ad hoc analysis, which is science-speak for "we looked at the data a different way after the fact." Regulators tend to squint hard at those. It's a bit like a student saying, "If you don't count the questions I got wrong, I aced the test."
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
If the efficacy story is murky, the durability story is crystal clear.
DURAVYU showed a 42% reduction in treatment burden compared to aflibercept on its standard dosing schedule. That result hit statistical superiority (p-value < 0.0001), which is about as convincing as it gets. In practical terms, patients on DURAVYU needed roughly two fewer injections through Week 56.
Even more striking: 76% of DURAVYU patients didn't need any supplemental treatments up to Week 32. Three out of four patients went more than seven months without needing another shot.
For anyone who's sat in a retina clinic waiting room, that's a big deal. Fewer injections means fewer trips to the doctor, less anxiety about a needle entering your eye, and lower risk of the rare but serious complications that come with each procedure.
How It Works (Without the Jargon)
DURAVYU isn't just a longer-lasting version of existing drugs. It's a fundamentally different delivery system.
Think of traditional anti-VEGF injections like pouring a glass of water: you get a big dose up front, and it gradually disappears. DURAVYU is more like a slow-drip coffee maker. The drug (vorolanib, a tyrosine kinase inhibitor) is embedded in a tiny bioerodible insert called Durasert E. A doctor injects it into the eye using a standard needle, and then the insert slowly dissolves over six to nine months, releasing a steady stream of medication.
The active ingredient itself works differently from older anti-VEGF therapies too. Instead of blocking the VEGF protein floating around in the eye's fluid, vorolanib targets the VEGF receptors inside cells. It also hits inflammation pathways (JAK1/IL-6), giving it a dual mechanism that older treatments don't offer.
On safety, the news was reassuring. Across more than 190 patients in four completed clinical trials, EyePoint has reported no drug-related safety concerns. The independent safety committee reviewed masked data multiple times during LUGANO and recommended continuing without any protocol changes.
Wall Street's Dilemma
This readout was supposed to be a binary event for EyePoint's stock: either the data validates the platform or it doesn't. Instead, investors got a Rorschach test.
Bulls will point to the durability data, the clean safety profile, and the strong non-inferiority signal once you account for the confounding subgroup. They'll argue that EyePoint can work with regulators to present the data in a favorable light, especially with a second pivotal trial (LUCIA) still ongoing.
Bears will point to the missed primary endpoint, full stop. Ad hoc analyses don't get you FDA approvals. And even if the subgroup explanation is scientifically valid, convincing a review panel to ignore 4% of your patients is an uphill battle. The second trial needs to deliver a clean win, or the whole program could be in trouble.
A Crowded Race to Fewer Needles
EyePoint isn't the only company chasing the "fewer injections" prize. Genentech's Susvimo (a surgically implanted, refillable port that releases ranibizumab) is already approved and offers about six months between refills. Ocular Therapeutix's Axpaxli delivers axitinib over six to twelve months via its own sustained-release implant.
Then there's the gene therapy wave. Regenxbio and AbbVie are developing sura-vec, which turns the eye into its own anti-VEGF factory by delivering a gene that produces the therapeutic protein continuously. 4D Molecular Therapeutics has a similar approach with 4D-150, though pivotal data isn't expected until 2027.
The competitive landscape reveals why DURAVYU's mixed results matter so much. In a market where multiple companies are racing toward the same goal (less poking, more seeing), a clean Phase 3 win separates contenders from also-rans.
What Comes Next
All eyes (pun absolutely intended) are now on LUCIA, EyePoint's second pivotal Phase 3 trial in wet AMD. If LUCIA delivers a clear non-inferiority win in the full dataset, EyePoint can argue that LUGANO was an anomaly caused by a small, confounding subgroup. Two trials pointing in the same direction would give regulators a much stronger package to evaluate.
If LUCIA misses too, the sustained-delivery dream doesn't die, but EyePoint's version of it might.
For patients stuck on monthly injection schedules, the stakes are simple: the science behind DURAVYU clearly works. The question is whether the clinical data can prove it cleanly enough to satisfy the FDA. Sometimes in drug development, a good drug with messy data is worse than no data at all.
Deals & M&A
4 min read
Sandoz Is Buying Its Biosimilar Future From China
Sandoz just committed up to $322 million to license biosimilars from a Chinese company most people have never heard of. The deal with Shanghai Henlius signals something bigger: China's biologics ecosystem has gone from follower to supplier for the world's largest biosimilar company.
